IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Debt
Debt-to-Equity Ratio-14.77
Current Ratio0.96
Quick Ratio0.73
Price-To-Earnings
Trailing P/E Ratio74.54
Forward P/E Ratio58.81
P/E Growth2.21
Sales & Book Value
Annual Sales$1.97 billion
Price / Sales10.81
Cash Flow$4.4105 per share
Price / Cash55.74
Book Value($0.62) per share
Price / Book-396.52
Profitability
EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins14.50%
Return on Equity-703.80%
Return on Assets21.21%
Miscellaneous
Employees7,600
Outstanding Shares86,590,000
Market Cap$20.88 billion
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories declared that its Board of Directors has approved a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Wednesday, August, 1st. The company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.06. The company had revenue of $580.75 million for the quarter, compared to analysts' expectations of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The firm's quarterly revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 earnings per share. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.
What price target have analysts set for IDXX?
6 equities research analysts have issued twelve-month price targets for IDEXX Laboratories' stock. Their forecasts range from $215.00 to $260.00. On average, they anticipate IDEXX Laboratories' share price to reach $238.00 in the next twelve months. This suggests that the stock has a possible downside of 3.2%. View Analyst Price Targets for IDEXX Laboratories.
What is the consensus analysts' recommendation for IDEXX Laboratories?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT) and Vermillion (VRML).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
- Mr. Jay Mazelsky, Exec. VP (Age 57)
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.25%), Fundsmith Equity Fund L.P. (5.12%), Renaissance Technologies LLC (2.51%), Bank of New York Mellon Corp (1.28%), Bank of New York Mellon Corp (1.28%) and Northern Trust Corp (1.19%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which institutional investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbus Circle Investors, Wells Fargo & Company MN, Bank of America Corp DE, Janus Henderson Group PLC, FMR LLC, Federated Investors Inc. PA and TCW Group Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Which institutional investors are buying IDEXX Laboratories stock?
IDXX stock was acquired by a variety of institutional investors in the last quarter, including Fundsmith Equity Fund L.P., Marshall Wace LLP, Ardevora Asset Management LLP, Worldquant Millennium Quantitative Strategies LLC, CIBC Private Wealth Group LLC, First Trust Advisors LP, Renaissance Technologies LLC and Baird Financial Group Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $245.84.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $20.88 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.
What is IDEXX Laboratories' official website?
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
